YD Life Science acquires approval of DR therapy for Phase 2a clinical trial in U.S.

Published: 2018-08-23 17:18:34

Updated: 2018-08-23 17:18:34

YD Life Science(CEO Jin-Woo Lee) announced on the 21^st that its diabetic retinopathy(DR) therapy ‘YD-312’ acquired final approval for a Phase 2a clinical trial from the U.S. Food and Drug Administration.

Diabetic retinopathy, a diabetes complication, is a dermatologic disease which affects eyes. It is caused by damage to the blood vessels of the light-sensitive issue with low-oxygen at the ret...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.